Trial Profile

A randomized, placebo-controlled phase 2b clinical study of PBI-4050 in patients with idiopathic pulmonary fibrosis (IPF)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 03 Jun 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 May 2021 According to a Liminal BioSciences media release, based on the interim pharmacokinetic results from the ongoing Fezagepras multiple ascending dose (MAD) study, the company has decided to stop its plans to move fezagepras into a Phase II clinical study in Idiopathic Pulmonary Fibrosis.
28 May 2021 Status changed from planning to discontinued, according to a Liminal BioSciences media release.
17 May 2021 According to a Liminal BioSciences media release, this trial is expected to begin in the first half of 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com